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Introduction
Cardiovascular diseases (CVD), especially stroke and
coronary heart disease (CHD), are the leading
causes of morbidity and mortality in Taiwan in the
past decades [1]. Bodies of evidence support the
importance of early detection of atherosclerosis
and its associated risk factors in the prevention and
treatment of atherosclerotic diseases. Carotid intima-
media thickness (IMT) measurement is widely used
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to associate the cardiovascular risk factors [2–10]
and CVD [11–13] in epidemiologic and clinical
studies in the past 20 years. Even though some
studies still debate over the statement of carotid IMT
as atherosclerosis [14,15], carotid IMT has been
established as an early predictor for the future car-
diovascular events, including acute myocardial
infarction (MI) and stroke [16–22]. With its high
reliability and reproducibility [23–25] and for the
high correlation between measured IMT and the
actual pathologic changes [26–27], ultrasound IMT
measurement of carotid artery has been widely
used in epidemiologic and clinical studies for the
detection and evaluation of early preclinical ather-
osclerosis. The structural changes of the carotid
arteries have been considered as a window for 
cardiovascular risk in apparently healthy indivi-
duals [28].
Measurements of Carotid
Atherosclerosis (CA) as 
Predictors of CVDs
Why use CA as the window of CVD? Many studies
have documented the measurements of IMT as good
predictors for MI and stroke [16–22]. Table 1 sum-
marizes some landmark population-based studies
that looked for carotid IMT as predicting markers for
CVD: the Rotterdam study, the Atherosclerosis Risk
in Communities (ARIC) study, and the Cardiovascular
Health Study (CHS). All these studies demonstrated
that carotid IMT was significantly associated with
future CVD events.
To evaluate the usefulness of carotid IMT as a pre-
dictor of CVD, the Rotterdam Study applied a nested
case-control design among 7,983 subjects with age
≥ 55 years who participated in the original cohort.
After mean duration of 2.7 years’ follow-up, a sample
of 1,373 subjects who remained free from MI and
stroke was studied. Stroke risk increased as common
carotid artery (CCA) IMT increased. The odds ratio
(95% confidence interval [CI]) for stroke per stan-
dard deviation increase (0.163mm) in CCA IMT was
1.41 (1.25–1.82). For MI, the corresponding odds
ratio (95% CI) was 1.43 (1.16–1.78). Based on a
short follow-up period, this study provides evidence
that an increased CCA IMT is associated with future
cerebrovascular accident (CVA) and CVD events [16].
After a mean follow-up of 4.6 years in the Rotterdam
study, a case-cohort approach was assessed to asso-
ciate the IMT at CCA, carotid bifurcation and internal
carotid artery (ICA) with the incident MI. The risk
ratios (95% CI) for MI associated with mean maxi-
mum IMT at CCA, bifurcation, ICA and the com-
bined measurements were 3.18 (1.83–5.54), 4.11
(2.10–8.05), 5.31 (1.77–15.9) and 6.27 (3.27–12.0),
respectively, for the comparisons between the high-
est and the lowest quartiles. The risk ratios (95%
CI) for MI per standard deviation increase of CCA,
bifurcation, ICA and combined IMT were 1.44 (1.28–
1.62), 1.34 (1.17–1.53), 1.12 (0.94–1.33) and 1.47
(1.31–1.65), respectively [17].
In the ARIC study, the relationship of IMT to CHD
incidence was assessed over 4–7 years of follow-up
(1987–1993) in four United States communities.
Participants composed of 7,289 women and 5,552
men with ages 45–64 years who were free of clinical
CHD at baseline. In sex-specific Cox proportional
hazard models adjusted only for age, race and center,
the hazard rate ratio (95% CI) comparing extreme
mean IMT (≥ 1 mm) with not extreme (< 1 mm) was
5.07 (3.08–8.36) for women and 1.85 (1.28–2.69)
for men [18]. Additionally, the association of mean
IMT to stroke incidence was assessed after 6–9
years’ follow-up (1987–1995) among those without
stroke at baseline. The hazard rate ratios (95% CI)
comparing extreme mean IMT values (≥ 1 mm) with
values less than 0.6 mm were 8.5 (3.5–20.7) for
women and 3.6 (1.5–9.2) for men [19].
In CHS, O’Leary and colleagues studied the
associations between carotid IMT and the incidence
of new MI or stroke in 5,858 subjects 65 years of
age or older. Of them 4,476 subjects were without
clinical CVD. Over a median follow-up period of
6.2 years, the incidence of cardiovascular events
was correlated with measurements of carotid IMT.
The relative risk of MI or stroke increased with IMT.
The association between cardiovascular events
and IMT remained significant after adjustment 
Ta
bl
e 
1.
C
ar
ot
id
 a
rt
er
y 
in
tim
a-
m
ed
ia
 t
hi
ck
ne
ss
 (
IM
T)
 a
s 
a 
pr
ed
ic
to
r 
fo
r 
ca
rd
io
va
sc
ul
ar
 d
is
ea
se
 (
C
VD
)
St
ud
y
Si
te
C
ha
ra
ct
er
is
tic
s 
of
 s
tu
dy
 s
ub
je
ct
s
Fo
llo
w
-u
p,
IM
T,
 m
m
C
ar
di
ov
as
cu
la
r 
di
se
as
e
R
ef
er
en
ce
A
ge
, y
r
n
yr
in
cr
ea
se
Ty
pe
R
is
k 
ra
tio
 (
95
%
 C
I)
R
ot
te
rd
am
C
C
A
≥
55
95
 s
tr
ok
e,
 9
9
M
I,
2.
7
0.
16
3
A
M
I
1.
43
 (
1.
16
–1
.7
8)
16
1,
37
3 
co
nt
ro
ls
St
ro
ke
1.
41
 (
1.
25
–1
.8
2)
C
C
A
≥
55
19
4
M
I, 
1,
87
9 
co
nt
ro
ls
4.
6
0.
21
M
I
1.
44
 (
1.
28
–1
.6
2)
17
B
if
0.
60
M
I
1.
34
 (
1.
17
–1
.5
3)
IC
A
0.
66
M
I
1.
12
 (
0.
94
–1
.3
3)
A
R
IC
M
ea
n,
 6
 c
ar
ot
id
45
–6
4
5,
55
2 
m
al
es
, 
4–
7;
* 
≥
1
m
m
 vs
.
C
H
D
1.
85
 (
1.
28
–2
.6
9)
*
18
si
te
s
7,
28
9 
fe
m
al
es
6–
9†
<
1
m
m
C
H
D
5.
07
 (
3.
08
–8
.3
6)
†
≥
1
m
m
 v
s.
St
ro
ke
3.
6 
(1
.5
–9
.2
)*
19
<
0.
6
m
m
St
ro
ke
8.
5 
(3
.5
–2
0.
7)
†
C
H
S
C
C
A
≥
64
4,
47
6
6.
2
0.
20
A
M
I
1.
24
 (
1.
12
–1
.3
8)
20
St
ro
ke
1.
28
 (
1.
16
–1
.4
2)
C
om
bi
ne
d 
M
I 
1.
27
 (
1.
17
–1
.3
8)
or
 s
tr
ok
e
IC
A
0.
55
A
M
I
1.
34
 (
1.
20
–1
.5
0)
St
ro
ke
1.
25
 (
1.
12
–1
.3
9)
C
om
bi
ne
d 
M
I o
r
1.
30
 (
1.
20
–1
.4
1)
st
ro
ke
*I
n 
m
al
es
; †
in
 fe
m
al
es
. C
I =
co
nf
id
en
ce
 in
te
rv
al
; C
C
A
 =
co
m
m
on
 ca
ro
tid
 a
rt
er
y;
 M
I =
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 A
M
I =
ac
ut
e 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 b
if 
=
bi
fu
rc
at
io
n;
 IC
A
 =
in
te
rn
al
 ca
ro
tid
 a
rt
er
y;
 A
RI
C
 =
A
th
er
os
cle
ro
sis
 R
isk
in
 C
om
m
un
iti
es
; C
H
D
 =
co
ro
na
ry
 h
ea
rt
 d
ise
as
e;
 C
H
S 
=
C
ar
di
ov
as
cu
la
r H
ea
lth
 st
ud
y.
T.C. Su, J.S. Jeng, B.S. Hwang, et al
114 J Med Ultrasound 2007 • Vol 15 • No 2
Carotid Atherosclerosis as a Window of CVD
115J Med Ultrasound 2007 • Vol 15 • No 2
for traditional risk factors. There was a progressive
increase in risk ratios (95% CI) for each quintile of
combined IMT, from the second quintile of 1.54
(1.04–2.28), to the fifth of 3.15 (2.19–4.52). The
results of separate analysis of MI and stroke paralleled
those for the combined end point. This study also
provides strong evidence indicating that increases in
carotid IMT are directly associated with an increased
risk of MI and stroke in older adults without a history
of CVD [20].
The Use of CA in Pharmacologic
Studies
The high reproducibility of carotid IMT measure-
ments also makes the application of IMT in many
observational studies and pharmacologic interven-
tional studies feasible. In Table 2, we summarized
the results of recent important clinical trials that use
carotid IMT as the surrogate outcome measures in
medications for treating the important risk factors
of CVDs, such as hyperlipidemia, hypertension and
hyperglycemia.
Lipid-lowering (LDL) therapies
In the 1990s, carotid ultrasound was first applied
in the evaluation of the cardiovascular protective
effects of cholesterol-lowering agents. PLAC II study
[29] was the earlier study to test whether the LDL
agent, pravastatin, compared with placebo, had a
beneficial effect on IMT progression over 3 years in
coronary patients. Although pravastatin significantly
reduced IMT progression by approximately 35%
in the CCA segment, this study did not demon-
strate a significant effect of LDL therapy. However,
REGRESS study [30] did show that pravastatin,
compared wth placebo, significantly decreased the
progression of IMT in coronary patients. In the
Kuopio Atherosclerosis Prevention Study (KAPS), 
a population-based primary preventive trial, it 
was found that LDL had beneficial effects on
atherosclerotic progression in carotid and femoral
arteries [31]. For the carotid artery segments (CCA
and bulb), the annual rate of progression in the
pravastatin group (0.017mm/year) was significantly
smaller than in the placebo group in which there
was progression of 0.031 mm/year at the overall
mean baseline IMT of 1.66 mm. This represents a
45% reduction in atherosclerotic progression.
ACAPS study [32] demonstrated that lovastatin,
compared with placebo, significantly decreased IMT
progression over 3 years in asymptomatic patients.
Reduction in carotid arterial wall thickness was also
noted in a randomized controlled clinical trial in
which lovastatin and dietary therapy were adopted
for hyperlipidemic intervention [33]. In two recent
trials, ASAP [34] and ARBITER [35] studies, aggressive
LDL with high dose atorvastatin (80 mg/day) was
compared with the conventional LDL doses of 
simvastatin or pravastatin, respectively. High dose
atorvastatin was proved to be superior in carotid
IMT regression compared with moderate LDL by
simvastatin (40 mg/day) in patients with familial
hypercholesterolemia [34] or pravastatin (40mg/day)
in patients that met National Cholesterol Education
Program II criteria for LDL therapy [35].
Anti-hypertensive medications
In randomized clinical trials, the beneficial effects of
anti-hypertensive agents in enhancing atherosclero-
sis regression or decreasing atherosclerosis progres-
sion in carotid arteries have also been established.
In an ancillary study of the International Nifedipine
GITS Study: Intervention as a Goal in Hypertension
Treatment (INSIGHT), CCA IMT progression was
compared between the treatments with either nifed-
ipine or diuretic for 4 years [36]. IMT progressed 
in the co-amilozide-treatment group but not in
nifedipine-treatment group. This study demonstrated
that agents with equal blood pressure lowering
effects may show a different efficacy on early carotid
IMT progression. The PREVENT study [37] has shown
that in coronary patients undergoing treatment for
over 3 years, amlodipine significantly decreased IMT
progression in comparison with placebo. In the
SECURE study [38], a total of 732 patients of ages
≥ 55 years who had vascular disease or diabetes and
at least one other risk factor but did not have heart
failure or a low left ventricular ejection fraction were
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randomly assigned to receive either ramipril 2.5mg/
day or 10 mg/day and vitamin E 400 IU/day or their
matching placebos. This study showed that long-
term treatment with ramipril had a beneficial effect
on atherosclerosis progression, while vitamin E was
neutral on atherosclerosis progression.
The European Lacidipine Study on Atherosclerosis
(ELSA) [39] was a randomized, double-blind trial
on 2,334 patients with hypertension. This study
intended to compare the effects of a 4-year treat-
ment based on either lacidipine or atenolol on CA,
the IMT in CCA and bifurcations. The greater efficacy
of lacidipine on carotid IMT progression and num-
ber of plaques, despite a smaller ambulatory blood
pressure reduction, indicates an antiatherosclerotic
action of lacidipine which is independent of its
antihypertensive action. The ELVERA trial was
designed to compare the effects of the calcium
channel blocker amlodipine and the angiotensin-
converting enzyme inhibitor lisinopril on IMT in the
elderly, previously untreated hypertensive individuals
[40]. After a long-term follow-up, amlodipine and
lisinopril reduced IMT to a similar extent in newly
diagnosed elderly hypertensive patients. These stud-
ies demonstrated that the cardio-protection of anti-
hypertensive agents might be mediated through
atherosclerosis regression.
Medications for hyperglycemia
Medications for diabetes mellitus (DM) or insulin
resistance have also been demonstrated to be 
beneficial for the regression of CA. Acarbose is an
α-glucosidase inhibitor that specifically reduces
postprandial glucose excursion by delaying the
release of glucose from disaccharides and complex
carbohydrates in the small intestine. Acarbose
treatment was found to be significantly associated
with reduced progression of carotid IMT in subjects
with impaired glucose tolerance, a high-risk popu-
lation for diabetes and atherosclerosis. The annual
increase of carotid IMT was reduced by approxi-
mately 50% in the acarbose group (0.007mm/year)
vs. the placebo group (0.013 mm/year) [41].
Rosiglitazone, an insulin sensitizer, was assessed
for the effect on CCA IMT progression in nondiabetic
coronary artery disease (CAD) patients. Consecutive
subjects (n = 92) with clinically stable, angio-
graphically documented CAD and without DM
were randomized in a double-blind manner to
receive placebo or rosiglitazone for 48 weeks.
Rosiglitazone-treated patients showed reduced IMT
progression, compared with the placebo group
(–0.012mm vs. +0.031mm; p=0.03). Rosiglitazone
reduced common carotid IMT progression in non-
diabetic CAD patients [42]. Another thiazolidine-
dione, pioglitazone, was compared with glimepiride
regarding the inhibitory effect on carotid IMT. At 
a study period of 72 weeks, the primary end point
of progression of mean carotid IMT was less in
group with pioglitazone vs. glimepiride (–0.001 mm
vs. +0.012 mm). The reduction of carotid IMT 
correlated with improvement in insulin resistance
and was independent of improvement in glycemic
control. In an 18-month treatment period in
patients with type 2 DM, pioglitazone could slow
the progression of carotid IMT, compared with
glimepiride [43].
Metformin, in combination with glibenclamide or
gliclazide, was associated with significantly reduced
progression of carotid IMT (0.003 and 0.032 mm/
year, respectively), compared with glibenclamide
alone (0.064 mm/year). Multiple regression analysis
revealed that use of metformin or gliclazide signif-
icantly and independently accounted for inhibition
of the progression of carotid IMT [44]. Thus, the
medications for controlling blood sugar also clearly
demonstrated the cardiovascular protective effects
by using the CA as indexes.
Measurement Issues
Instrumentation
High-resolution B-mode ultrasonography allows
for the observation of carotid arterial structures,
including IMT and atherosclerotic plaques. Carotid
ultrasound studies require a machine equipped
with 5- to 12-MHz linear-array transducers. In addi-
tion, a software package for vascular ultrasound is
also required. In general, duplex scanning refers to
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Fig. 1. (A) The schematic overview of intima-media thickness (IMT) at carotid arteries and the site of measurements. (B) The real
measurements of IMT at distal common carotid artery (CCA).
an ultrasound scanning procedure recording both
B-mode images of gray scale of interested arteries
and Doppler information of velocity or resistance of
interested artery segments [45].
Protocol of ultrasound measurements
Carotid ultrasonography is performed by trained
physicians or ultrasonographers. The patients are
kept supine with the neck extended in mild lateral
rotation. The examination should include the obser-
vation of longitudinal and transverse views of the
extracranial carotid artery (ECCA) bilaterally. A small
soft pillow is favored to support the neck in a fixed
position while the examination is undertaken.
Examinations should be recorded on super-VHS
videotape or digitalized memory system for subse-
quent off-line analysis [8–10,45]. A moving-image
clip of the carotid bulb and CCA with a duration of
5 seconds is acquired and stored in digital format
for subsequent offline analysis. At analysis, each
image of carotid IMT is recalled with magnification
and measured.
ECCA ultrasound measurements
Carotid end-organ disease is assessed by mean and
maximal IMTs at the CCAs and by ECCA plaque
scores. The mean and maximal IMTs on the CCA
proximal to the carotid bifurcation are obtained
bilaterally. The CCA1 and CCA2 are points located
0 to 1 cm and 1 to 2 cm, respectively, on the CCA
distal from the carotid bifurcation. ECCA segments,
including the proximal and distal CCA (> 20 mm
and 0–20 mm distal to the bulb bifurcation, respec-
tively), bulb, ICA and external carotid artery, are
examined bilaterally [8,9].
IMT measurements
Current ultrasonographic technology does not per-
mit reliable separate measurement of the intima
and the media; hence, the standard measurement
is combined IMT at the far wall. The IMT of the
posterior (or far) wall of the distal CCA is measured
as the distance from the leading edge of the first
echogenic line (lumen-intima interface) to the
leading edge of the second line (media-adventitia
interface) (Fig. 1) [46]. The measurement of mean
and maximal IMT at the CCA 0–20 mm proximal
to the carotid bifurcation will be obtained bilater-
ally; however, which segment or width of meas-
ured site will depend on the protocol of different
studies (Fig. 1). Carotid plaque is skipped to pre-
vent the overestimation of the real IMT of individ-
uals. It is required to differentiate carotid IMT from
atherosclerotic plaque. CCA IMT is a double-line
observed by ultrasonography in a longitudinal view.
The carotid plaque is a focal structure encroaching
the arterial lumen of at least 0.5 mm or 50% of the
surrounding IMT, or an intima-media complex
thickness > 1.5 mm [47]. Automated measurement,
the mean maximal value of 150 measurements on
Carotid Atherosclerosis as a Window of CVD
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a 10 mm segment of the CCA, is efficient, reliable
and less time-consuming than manual measure-
ment. A minimum of 10 mm length of the CCA
and a high-quality image acquisition are better for
IMT measurement.
Reliability of measurements
A critical component in scientific studies of most
biologic variables is the variation or error in meas-
urements. The measurement variability or error of
carotid IMT can be decreased by using ultrasound
images from both the right and the left carotid
arteries and by the use of an automated analyzing
system with automated edge detection which greatly
simplifies the reading of ultrasound images with
sustained low variability [48,49]. For further com-
parison and application of the measurements of
IMT and carotid plaque, the accuracy of measure-
ments and reliability study for the test-retest should
be documented, including the interobserver and
intraobserver, or inter-reader and intra-reader reli-
ability. In our previous study, the interobserver cor-
relation coefficients were 0.86 to 0.93, and the
intraobserver correlation coefficients were 0.70 to
0.87 for both sides of CCA IMT measurements [24].
The detection limit of measurements depends on
the duplex ultrasound system and the software for
this application.
Where to measure? CCA, ICA or carotid bulb?
CCA is favored as the measurement site over other
locations of ECCA, such as ICA and carotid bulb, in
most epidemiologic studies [2,45,50,51]. CCA is
considered as the segment of choice, possibly
because the IMT variability associated with this seg-
ment is lower in comparison with other segments.
Not only is the reliability of the IMT measurements
reported to be higher but also more accessible at
the CCA than at the carotid bulb and ICA [50,51].
The far wall of the ECCA is clearer and more homog-
enous and consistent; therefore, we suggest that
IMT at the far wall of the carotid arteries is the
favored measurement site.
ECCA atherosclerotic plaque scoring
There are several methods of carotid plaque quan-
tification applied in clinical or epidemiologic stud-
ies. A plaque scoring quantifying method, modified
from that of Sutton et al, has been described pre-
viously [8,13] and is shown in Fig. 2. Briefly, a focal
thickening of IMT with over 50% of thickness than
the adjacent IMT is considered as an atheroscle-
rotic plaque. A grade is assigned for each chosen
segment: grade 0, normal or no observable plaque;
grade 1, one small plaque with diameter stenosis of
< 30%; grade 2, one medium plaque with 30–49%
diameter stenosis or multiple small plaques; grade 3,
one large plaque with 50–99% diameter stenosis
or multiple plaques with at least 1 medium plaque;
and grade 4, 100% occlusion. The total plaque score
is calculated by adding up the plaque grades at 10
segments of the ECCA. Reproducibility of the ECCA
plaque grade scoring also expresses good agree-
ment with a κ value of 0.70 [25].
A B
Fig. 2. (A) The extracranial carotid artery (ECCA) plaque score of 2 at bulb. (B) ECCA score of 2 at bulb and common carotid
artery (CCA).
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Carotid stenosis and occlusion
Currently, the degree of carotid stenosis is based on
conventional angiography of the carotid arteries.
Two different methods are widely used: (1) the distal
method, also known as “North American Sympto-
matic Carotid Endarterectomy (NASCET) method”
[52], calculating the ratio of the minimal residual
diameter of the stenotic segment; (2) the local me-
thod, also known as “European Carotid Surgery Trial
(ECST) method” [53], calculating the ratio of the
minimal residual diameter of the stenotic segment
to the presumed former diameter of the same seg-
ment. In general, the ECST method leads to 10–20%
higher degree of carotid stenosis than the NASCET
method. The ultrasonographic measurement of ca-
rotid stenosis should be determined against either
the ECST or the NASCET method [54].
According to the various validity ultrasound
studies, some methods are proven to be highly
accurate in quantification of ICA stenosis [55–57]:
(1) The ICA peak systolic velocity (PSV) method:
the highest PSV on the stenotic site. As the
degree of luminal stenosis of the ICA > 50%,
the PSV increases to > 1.25 m/s. In 70–95%
stenosis, the PSV reaches to > 2.5 m/s. In ICA
stenosis higher than 95%, the PSV decreases
due to a significant reduction of the blood
flow through the stenotic segment. Inability to
detect any residual flow signals in the stenotic
segment, it suggests ICA occlusion.
(2) The ICA/CCA PSV ratio method: dividing the
ICA intrastenotic PSV by the PSV derived from
the ipsilateral CCA 3 cm proximal to the bifur-
cation. In ICA stenosis < 50%, 50–69%, and
70–99%, the ICA/CCA PSV ratios are < 2, 2–4
and > 4, respectively. 
(3) The cross-sectional area reduction method: the
degree of luminal stenosis is determined by
the cross-sectional area reduction through the
transverse view of the stenotic ICA. In ICA steno-
sis < 50%, 50–69%, and 70–99%, the cross-
sectional area reduction are < 75%, 75–90%,
and 90–99%, respectively.
In addition to the aforementioned methods, there
are some other methods applied in quantification
of ICA stenosis, including mean flow velocity and
end-diastolic flow velocity on the stenotic site,
spectrum analysis, ICA/CCA mean flow velocity
ratio, color-Doppler flow, and indirect methods
(supraorbital Doppler flow and ipsilateral intracra-
nial ICA flow).
Previous Studies in Taiwan
Jeng et al first documented the feasibility of carotid
ultrasound in cardiovascular research in Taiwan in
1994 [13]. Consecutive 367 ischemic stroke patients
were selected from a medical center to study the
frequency of carotid stenosis and its risk factors.
Severe ECCA stenosis of ≥ 50% was found in 32%
of patients with cortical infarct, 3% with subcorti-
cal infarct, 7% with vertebrobasilar artery infarct,
21% with cardioembolism, and 12% of all ischemic
stroke patients. The extent and severity of ECCA
atherosclerosis were more prominent in patients
with cortical infarct than with other types of
ischemic stroke. In the following stroke registry
study conducted at National Taiwan University
Hospital, the frequency of ECCA stenosis remained
at 12% of ischemic stroke and 27% of transient
ischemic attack patients [58,59].
Pan et al studied the association between vas-
cular risk factors, particularly coagulation profiles,
and CA [7]. The odds ratio of the highest tertile to
the lowest tertile of factor VIIIc for CA was 3.35.
There was a positive correlation between factor
VIIIc and the presence of carotid plaques.
Su et al investigated the determinants of ECCA
atherosclerosis in patients with hypertension in
Taiwan. Hypertensive patients (146 with hyperten-
sion and 117 with borderline hypertension) and 270
normotensive adults were recruited from the Chin-
Shan Community Cardiovascular Cohort (CCCC). 
A significant dose-response relationship was found
between the status of hypertension and the severity
of CA. Compared with the normotensive subjects,
the odds ratios (and 95% CIs) for the hypertensive
patients to develop CA were 5.0 indexed by maximal
CCA IMT ≥ 75th percentile, 3.7 by ECCA score > 6,
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and 4.8 by carotid stenosis ≥ 50%. This study clearly
documented that hypertension strongly influences
CA. The findings reinforced the hypothesis that
hypertension has a major role in the pathogenesis
of atherosclerosis [8]. In the same study, Su et al
also found that pulse pressure was strongly asso-
ciated with CA in patients with hypertension, after
taking into account aortic regurgitation. In terms
of risk stratification, pulse pressure was more impor-
tant in hypertensives than in normotensives, which
seems to imply that pulsatile hemodynamic com-
ponent of BP is crucial in the association with 
atherosclerosis [60].
Since the adoption of vegetarian diets as part of
a healthy lifestyle has become popular, the cardio-
vascular effects of long-term vegetarianism need to
be explored. Su et al studied the micronutrient
imbalance, including blood levels of vitamin B12,
homocysteine and soluble vascular cell adhesion
molecule-1, in vegetarians and their associations with
CA in 57 healthy postmenopausal vegetarians and
61 age-matched omnivores. They found that there
was no significant difference in CA between appar-
ently healthy postmenopausal vegetarians and omni-
vores. The findings of elevated homocysteine and
soluble vascular cell adhesion molecule-1 in vege-
tarians indicate the importance of avoidance of B12
deficiency [10]. The relationship between time fac-
tors of elevated BP and CA is still unclear. The asso-
ciations between time-weighted average 24 hour
ambulatory systolic BP, duration of hypertension in
years (hypertension-year), and CA were investigated
in a petrochemical company sample of 95 executives
and 91 gender- and age-matched non-executive
employees. In this work-site related cardiovascular
promotion program, we found that both time-
weighted average ambulatory systolic BP and
hypertension-year were two major determinants
for carotid IMT and CA, which seems to imply that
both short-term and long-term durations of elevated
BP are probably crucial in the pathogenesis of CA [9].
Because of the high prevalence of hepatitis B infec-
tion in Taiwan, we tested the hypothesis of chronic
infection of hepatitis B virus and preclinical CA.
Among 508 subjects who participated in the health
examination, we noted that hepatitis B virus seropos-
itivity in the 87 subjects was not associated with an
increased severity of CA [61].
One study analyzed the data from physical exam-
ination at a medical center between 1996 and 1998
[62]. The presence of CA was associated with the
increase in the counts of all leukocyte, neutrophil
and monocyte; after adjustments for age and body
mass index, there were significant positive links
between these three leukocyte counts and the
severity of CA in 571 non-smoking subjects, in terms
of either the sum score of all carotid plaques or the
score of the most severe carotid plaque. On the
contrary, in female non-smokers (n=614), there was
no such significant link between leukocyte counts
and CA. This study suggested that monocytes and
neutrophils are the main types of leukocytes involved
in atherosclerosis [62]. Between 1998 and 2001,
another study used the data from physical exami-
nation to evaluate the determinants of carotid IMT
in 1,781 asymptomatic subjects [63]. The mean
IMT was 0.68 ± 0.12 and 0.66 ± 0.11 mm for men
and women, respectively. Among them, 37% had
carotid plaques which were positively associated
with age and IMT. Age, systolic blood pressure and
fasting blood sugar were independent risk factors
related to both CA and thicker IMT [63].
Some parts of Taiwan are known to be endemic
areas of high arsenic exposure. An interesting study
was conducted to examine the biologic gradient
between ingested inorganic arsenic and CA in 199
male and 264 female adult residents from the
southwestern area of endemic arseniasis in Taiwan
[64]. Indices of long-term exposure to ingested
arsenic were all significantly associated with preva-
lence of CA in a dose-response relationship. The
biologic gradient remained significant after adjust-
ment for associated covariates. The multivariate-
adjusted odds ratio (95% CI) was 3.1 (1.3–7.4) for
those who had a cumulative arsenic exposure of
≥20mg/L-years compared with those without expo-
sure to arsenic from drinking artesian well water.
This study demonstrated that CA by ultrasonogra-
phy is associated with ingested inorganic arsenic in
a pattern of biologic gradient [64].
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Conclusion
Application of carotid ultrasound in clinical practice is
feasible. The proper use of ultrasound, measurement
protocols and available IMT software is important to
obtain an accurate and reliable image for clinical
research. The potential indications for risk stratifica-
tion that is proposed in a report from the American
Society of Echocardiography and the Society of
Vascular Medicine and Biology [45] are as follows:
“In asymptomatic persons over 45 years, carefully
performed carotid ultrasound examination with IMT
measurement can add incremental information to
traditional risk factor assessment. In experienced lab-
oratories, this test can now be considered for further
clarification of CHD risk assessment at the request of
a physician [65].” However, the noninvasive cardio-
vascular testing should be arranged based on physi-
cians’ recommendation and referral and only after a
careful consideration of known medical history and
evaluation of major standard cardiovascular risk fac-
tors by office-based techniques [66]. Some studies
also suggest that high-risk patients, such as those
with existing CVD (stroke or CHD), hypertension,
higher pulse pressure, age over 45 years, DM, meta-
bolic syndrome and hyperlipidemia, may benefit
from this simple and noninvasive examination in
the perspectives of primary or secondary prevention
of CVD.
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